Characteristics of patients receiving vasopressors

Heart & Lung : the Journal of Critical Care
Julie BenbenishtyYoram Weiss

Abstract

Patients receiving intensive care frequently need pharmacologic support of their blood pressure because of shock. In some patients, shock is so severe that extremely high doses of vasopressors are needed to elevate their blood pressure. We sought to ascertain the maximal dose of vasopressors administered to patients, and to describe the population of patients receiving vasopressors in one intensive care unit. All adult patients admitted in 2001 to a 10-bed surgical unit in a university hospital, and receiving a vasopressor agent for 1 hour or more, underwent recordings of their demographic data, diagnoses upon admission, Acute Physiological and Chronic Health Evaluation (APACHE) II scores, vasopressors (including type, initial dose, dose increases, and maximal dose), number of days administered, complications, and mortality. Of 689 patients whose charts were reviewed, 72 received vasopressors. The mean age was 65 ± 21.4 years, and 66% were male. The mean APACHE II scores were 24 ± 6.2. The administration of .5 μg/kg/minute of norepinephrine or epinephrine resulted in 96% sensitivity and a specificity of 76% for the likelihood of mortality. Using Kaplan-Meyer curves, those patients receiving less than .5 μg/kg/minute demonstrate...Continue Reading

References

Oct 1, 1985·Critical Care Medicine·W A KnausJ E Zimmerman
Aug 31, 2000·Critical Care Medicine·C MartinX Thirion
Aug 14, 2003·JAMA : the Journal of the American Medical Association·Charles L SprungUNKNOWN Ethicus Study Group
Mar 11, 2004·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Deborah CookDaren Heyland
Apr 20, 2004·Critical Care Medicine·R Phillip DellingerUNKNOWN Surviving Sepsis Campaign Management Guidelines Committee
Dec 26, 2007·Critical Care Medicine·R Phillip DellingerUNKNOWN World Federation of Societies of Intensive and Critical Care Medicine
Aug 16, 2008·American Journal of Respiratory and Critical Care Medicine·Eric GerstelJ Randall Curtis

❮ Previous
Next ❯

Citations

Aug 23, 2012·Chest·Samuel M BrownAlan H Morris
Oct 24, 2013·Critical Care Research and Practice·Estevão BassiLuciano Cesar Pontes Azevedo
Feb 2, 2013·World Journal of Surgery·Marc KastrupClaudia Spies
May 14, 2016·The Annals of Thoracic Surgery·Hagen BombergHans-Joachim Schäfers
Sep 16, 2016·The Annals of Pharmacotherapy·Janet Y WuTodd W Rice
Feb 2, 2017·Journal of Intensive Care Medicine·Jason A Ferreira, Brittany D Bissell
Jan 6, 2016·Journal of Neurosurgical Anesthesiology·Omar TujjarFabio S Taccone
Apr 4, 2018·Critical Care Medicine·Mahrukh S RizviOgnjen Gajic
Nov 22, 2018·Transplantation·Eleonora De MartinPrashant Bhangui
Jul 25, 2019·Journal of Thrombosis and Haemostasis : JTH·Jerrold H LevyTheodore E Warkentin
Jan 4, 2013·American Journal of Critical Care : an Official Publication, American Association of Critical-Care Nurses·Donna Döpp-Zemel, A B Johan Groeneveld
Sep 13, 2019·Intensive Care Medicine Experimental·Osamu FujiwaraPerenlei Enkhbaatar
Apr 21, 2017·Annals of Intensive Care·Thomas AuchetBruno Levy
Jul 6, 2019·Current Pharmaceutical Design·Hans KnotzerAxel Kleinsasser
Apr 9, 2020·Critical Care : the Official Journal of the Critical Care Forum·Jamel Ortoleva, Frederick C Cobey
May 20, 2020·Critical Care Explorations·Robert SbertoliSadashiv Santosh
Jan 1, 2013·World Journal of Emergency Medicine·Xue-Zhong XingKe-Lin Sun
May 4, 2021·The Journal of Surgical Research·Kathleen E SingerMichael D Goodman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.